Develops FDA-cleared eye-tracking devices and software that measure over 88 unique neurological test variables, providing objective assessments of brain health and cognitive function. These tools enable healthcare providers to diagnose and monitor neurological disorders, including long COVID-related deficits, with standardized clinical tests and normative data across 200+ customer sites.
Funding
Funding not disclosed
Founders
Product
Problem
Diagnosing and monitoring neurological disorders often relies on subjective assessments, leading to potential inaccuracies and delays in treatment. Traditional neurological testing methods may lack the sensitivity to detect subtle changes in brain function, particularly in early stages or for conditions like long COVID.
Solution
Spryson offers FDA-cleared eye-tracking devices and AI-powered software that provide objective, quantitative assessments of brain health and cognitive function. The NeuroAI platform captures subtle neurological markers through advanced eye-tracking technology, identifying patterns for earlier diagnosis and personalized treatment planning. By measuring over 88 unique neurological test variables, Spryson enables healthcare providers to diagnose and monitor a range of neurological disorders, including Parkinson's disease, traumatic brain injury (TBI), and long COVID-related deficits. The platform's multi-functional capabilities support early detection, progression monitoring, and treatment optimization, providing clinicians with real-time data to enhance diagnostic accuracy.
Target Audience
The primary target audience includes healthcare providers, such as neurologists and general practitioners, as well as clinical researchers focused on neurological disorders, TBI, and cognitive function.
Features
- Advanced eye-tracking technology captures subtle neurological markers invisible to traditional methods.
- AI-driven analytics identify patterns for earlier diagnosis and personalized treatment planning.
- PD-Check technology applies for FDA Breakthrough Device Status for Parkinson's disease detection.
- Non-invasive assessment combines eye-tracking with proprietary neurological biomarkers.
- Real-time processing delivers results in minutes for TBI/concussion diagnosis.
- Normative data across 16 clinical tests.
- Integration of biometric data with medical history for comprehensive assessment.
- Research integration continuously improves through real-world data collection.